EUVIMEDEUVIMED entdecken
Kohortenstudie

Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort Study

Daman Preet Kaur, Magda Bucholc, David P Finn, Stephen Todd, Kong Fatt Wong-Lin, Paula L McClean

Journal of Alzheimer's Disease · 2024

DOI: 10.3233/jad-230456 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Daman Preet Kaur und 5 weiteren Autor:innen. Beteiligte Einrichtung: Personalised Medicine Centre, School of Medicine, Ulster University, Altnagelvin Hospital, Derry/Londonderry, Northern Ireland, UK. Hauptthemen laut MEDLINE: Disease Progression, Dementia, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Clinical Dementia Rating Scale Sum of Boxes (CDRSOB) score is known to be highly indicative of cognitive-functional status and is regularly employed for clinical and research purposes.

Objective

Our aim is to determine whether CDRSOB is consistent with clinical diagnosis in evaluating drug class associations with risk of progression to mild cognitive impairment (MCI) and dementia.

Methods

We employed weighted Cox regression analysis on longitudinal NACC data, to identify drug classes associated with disease progression risk, using clinical diagnosis and CDRSOB as the outcome.

Results

Aspirin (antiplatelet/NSAID), angiotensin II inhibitors (antihypertensive), and Parkinson’s disease medications were significantly associated with reduced risk of progression to MCI/dementia and Alzheimer’s disease medications were associated with increased MCI-to-Dementia progression risk with both clinical diagnosis and CDRSOB as the outcome. However, certain drug classes/subcategories, like anxiolytics, antiadrenergics, calcium (Ca2+) channel blockers, and diuretics (antihypertensives) were associated with reduced risk of disease progression, and SSRIs (antidepressant) were associated with increased progression risk only with CDRSOB. Additionally, metformin (antidiabetic medication) was associated with reduced MCI-to-Dementia progression risk only with clinical diagnosis as the outcome.

Conclusions

Although the magnitude and direction of the effect were primarily similar for both diagnostic outcomes, we demonstrate that choice of diagnostic measure can influence the significance of risk/protection attributed to drug classes and consequently the conclusion of findings. A consensus must be reached within the research community with respect to the most accurate diagnostic outcome to identify risk and improve reproducibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionDementiaCognitive DysfunctionHumansMaleFemaleLongitudinal StudiesAgedProspective StudiesAged, 80 and overCohort StudiesMental Status and Dementia TestsAntihypertensive Agents

Stichwörter der Autor:innen

Alzheimer’s diseaseCDRSOBanticoagulantsantidepressantsantihypertensivesdementiadiagnosismetforminmild cognitive impairmentrisk factors

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Personalised Medicine Centre, School of Medicine, Ulster University, Altnagelvin Hospital, Derry/Londonderry, Northern Ireland, UK.
  • Intelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Derry/Londonderry, Northern Ireland, UK.
  • Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, University of Ireland, Galway, Ireland.
  • Altnagelvin Area Hospital, Western Health and Social Care Trust, Derry/Londonderry, Northern Ireland, UK.

Zitieren

APA

Kaur, D. P., Bucholc, M., Finn, D. P., Todd, S., Wong-Lin, K. F., & McClean, P. L. (2024). Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230456

Vancouver

Kaur DP, Bucholc M, Finn DP, Todd S, Wong-Lin KF, McClean PL. Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort Study. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-230456

BibTeX
@article{Kaur2024,
  author = {Kaur, Daman Preet and Bucholc, Magda and Finn, David P and Todd, Stephen and Wong-Lin, Kong Fatt and McClean, Paula L},
  title = {Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort Study},
  journal = {Journal of Alzheimer's Disease},
  year = {2024},
  doi = {10.3233/jad-230456}
}
Kostenlos starten →